OSMI-1
Based on 48 publication(s) in Google Scholar
OSMI-1 is a cell-permeable O-GlcNAc transferase (OGT) inhibitor with an IC50 value of 2.7 μM. OSMI-1 inhibits protein O-linked N-acetylglucosamine (O-GlcNAcylation) in several mammalian cell lines without qualitatively altering cell surface N- or O-linked glycans.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.88%
- CAS No.: 1681056-61-0
- Formule: C28H25N3O6S2
- Masse moléculaire:563.64
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
Metabolism/Protease Compound Library
HY-L012
-
Neuronal Signaling Compound Library
HY-L013
-
Lipid Metabolism Compound Library
HY-L091
-
Heterocyclic Compound Library
HY-L138
-
Metabolic Enzyme Compound Library
HY-L146
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
Publications Citing Use of MedChemExpress (MCE) OSMI-1
More- Signal Transduct Target Ther. 2023 Feb 10;8(1):63. [Abstract]
- Cell Mol Immunol. 2025 Jan;22(1):68-82. [Abstract]
- Nat Commun. 2025 Jul 1;16(1):6016. [Abstract]
- Nat Commun. 2024 Jan 4;15(1):252. [Abstract]
- Adv Sci (Weinh). 2025 Oct 14:e10662. [Abstract]
- Int J Oral Sci. 2026 Apr 6;18(1):32. [Abstract]
- Mol Ther. 2025 Dec 3;33(12):6146-6159. [Abstract]
- J Hazard Mater. 2024 Dec 5:480:135952. [Abstract]
- Cell Commun Signal. 2023 Sep 22;21(1):255. [Abstract]
- Dev Cell. 2025 Sep 3:S1534-5807(25)00530-1. [Abstract]
- Acta Pharmacol Sin. 2025 Jul;46(7):2041-2055. [Abstract]
- Free Radic Biol Med. 2025 Oct 25.
- Clin Sci. 2025 Oct 22;139(20):1163-1185. [Abstract]
- Cell Death Discov. 2023 May 15;9(1):163. [Abstract]
- Clin Transl Med. 2024 Jan;14(1):e1531. [Abstract]
- J Anim Sci Biotechnol. 2025 Sep 20;16(1):127. [Abstract]
- Mol Med. 2024 Oct 18;30(1):180. [Abstract]
- Ecotoxicol Environ Saf. 2024 Aug 23:284:116931. [Abstract]
- Commun Biol. 2025 Dec 18;8(1):1783. [Abstract]
- Commun Biol. 2025 Jul 29;8(1):1118. [Abstract]
- J Nutr Biochem. 2025 Dec 6:150:110227. [Abstract]
- Int J Oncol. 2023 Aug;63(2):90. [Abstract]
- Int Immunopharmacol. 2025 Sep 23:162:115158. [Abstract]
- Mol Pharm. 2024 Jan 1;21(1):102-112. [Abstract]
- J Physiol. 2025 May 11. [Abstract]
- Biochim Biophys Acta Mol Basis Dis. 2026 Aug;1872(6):168281. [Abstract]
- FASEB J. 2024 Jul 31;38(14):e23844. [Abstract]
- Cell Signal. 2026 Jun 26:146:112694. [Abstract]
- Reproduction. 2026 Feb 5;171(2):xaag005. [Abstract]
- Int Dent J. 2025 Oct 8;75(6):103897. [Abstract]
- Cytokine. 2025 Apr 19:191:156943. [Abstract]
- Mol Hum Reprod. 2024 Feb 1;30(2):gaae003. [Abstract]
- Toxicol Appl Pharmacol. 2024 Mar:484:116882. [Abstract]
- Am J Physiol Gastrointest Liver Physiol. 2026 Feb 1;330(2):G170-G188. [Abstract]
- Am J Physiol Gastrointest Liver Physiol. 2025 Jun 1;328(6):G746-G759. [Abstract]
- Funct Integr Genomics. 2026 May 25;26(1):109. [Abstract]
- Autoimmunity. 2025 Dec;58(1):2576881. [Abstract]
- Microvasc Res. 2023 Mar:146:104468. [Abstract]
- PLoS One. 2026 Feb 10;21(2):e0341971. [Abstract]
- Immunol Invest. 2026 May;55(4):750-773. [Abstract]
- Toxicon. 2026 Apr 1:273:109018. [Abstract]
- Biochem Biophys Res Commun. 2026 Aug 20:827:154043. [Abstract]
- bioRxiv. 2026 Apr 15.
- Res Sq. 2026 Mar 5.
- bioRxiv. 2026 Jan 26.
- Res Sq. 2025 May 15.
- Res Sq. 2025 Apr 13.
- Research Square Print. 2023 Jan 25.
Customer Validation & Images
-
WB
-
ELISA
-
RT-PCR
-
Histological Imaging/Staining
-
WB
Activité biologique
IC50: 2.7 μM (O-GlcNAc transferase)[1]
OSMI-1 (50 μM; 24 hours; CHO cells) treatment decreases the viability by about 50% after 24 hours[1].
OSMI-1 (10-100 μM; 24 hours; CHO cells) treatment reduces global O-linked N-acetylglucosamine (O-GlcNAcylation) a dose-dependent manner. OSMI-1 inhibits OGT activity in cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:CHO cells
-
Concentration:50 μM
-
Incubation Time:24 hours
-
Result:Viability decreased by about 50% after 24 hours.
-
Cell Line:CHO cells
-
Concentration:10 μM, 25 μM, 50 μM, 100 μM
-
Incubation Time:24 hours
-
Result:Reduced global OGlcNAcylation in a dose-dependent manner.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 1681056-61-0
-
Appearance Solid
-
Masse moléculaire 563.64
-
Formule C28H25N3O6S2
-
Color White to light yellow
-
SMILES
O=C(N(CC1=CC=CS1)CC2=CC=CO2)[C@H](NS(C3=CC(C=C4)=C(C=C3)NC4=O)(=O)=O)C5=CC=CC=C5OC
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (48)
-
Journal Impact Factor
-
Most Recent
-
Signal Transduct Target Ther
O-GlcNAcylation of YTHDF2 promotes HBV-related hepatocellular carcinoma progression in an N6-methyladenosine-dependent manner. [Abstract]2023 Feb 10;8(1):63. PMID: 36765030
OSMI-1 purchased from MedChemExpress. Usage Cited in: Signal Transduct Target Ther. 2023 Feb 10;8(1):63. [Abstract]
OSMI-1 (20 μΜ; 12 h) downregulates the O-GlcNAcylation in both HepG2-HBV1.3 cells (fig j) and Huh7-HBV1.3 cells (fig k).
-
Cell Mol Immunol
Dynamic O-GlcNAcylation governs long-range chromatin interactions in V(D)J recombination during early B-cell development. [Abstract]2025 Jan;22(1):68-82. PMID: 39627609
OSMI-1 purchased from MedChemExpress. Usage Cited in: Cell Mol Immunol. 2025 Jan;22(1):68-82. [Abstract]
Representative western blot showing changes in O-GlcNAc levels in total bone marrow (BM) cells and early B (CD11b–IgM–B220+) cells from mice intraperitoneally injected with OSMI-1 (1 mg/day 10 days).
-
Nat Commun
2025 Jul 1;16(1):6016. PMID: 40593722 -
Nat Commun
Cullin5 drives experimental asthma exacerbations by modulating alveolar macrophage antiviral immunity. [Abstract]2024 Jan 4;15(1):252. PMID: 38177117
OSMI-1 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Jan 4;15(1):252. [Abstract]
ELISA was performed to determine IFN-β concentration in the BALF of the indicated mice (Intraperitoneally with 200 µl 1 mg/kg OSMI-1 6 h before PR8 infection, followed by once-daily administration on days 14–15).
OSMI-1 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Jan 4;15(1):252. [Abstract]
Relative influenza virus content in the mice (Intraperitoneally with 200 µl 1 mg/kg OSMI-1 6 h before PR8 infection, followed by once-daily administration on days 14–15) lung tissues was quantified based on M protein levels measured via RT-qPCR and shown as ΔCt fold change.
OSMI-1 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Jan 4;15(1):252. [Abstract]
Periodic acid-Schiff (PAS), hematoxylin and eosin (H&E), and Masson’s trichome-stained lung tissues of the indicated mice (Intraperitoneally with 200 µl 1 mg/kg OSMI-1 6 h before PR8 infection, followed by once-daily administration on days 14–15).
OSMI-1 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Jan 4;15(1):252. [Abstract]
Immunoblotting of P-TBK1, TBK1, P-IRF3, IRF3, and β-actin in lysates of BMDMs stimulated by 4 μg/ml Poly(I:C) for the indicated times and pretreated with 20 μg/ml OSMI-1 for 30 min.
-
Adv Sci (Weinh)
ACE-mediated Glycosylation Stabilizes PSAP To Promote GPR37-dependent Macrophage-Nucleus Pulposus Cells Crosstalk and TGFβ Signaling in Alleviating Intervertebral Disc Degeneration. [Abstract]2025 Oct 14:e10662. PMID: 41085015 -
Int J Oral Sci
2026 Apr 6;18(1):32. PMID: 41936590 -
Mol Ther
Targeting O-GlcNAcylated METTL3 impedes MDS/AML progression via diminishing SRSF1 m6A modification. [Abstract]2025 Dec 3;33(12):6146-6159. PMID: 40914805 -
J Hazard Mater
Low-dose deoxynivalenol exposure triggers hepatic excessive ferritinophagy and mitophagy mitigated by hesperidin modulated O-GlcNAcylation. [Abstract]2024 Dec 5:480:135952. PMID: 39341193 -
Cell Commun Signal
2023 Sep 22;21(1):255. PMID: 37736724 -
Dev Cell
A pathological role of O-GlcNAcylation-driven TR11B production and function in lung adenocarcinoma. [Abstract]2025 Sep 3:S1534-5807(25)00530-1. PMID: 40930100 -
Acta Pharmacol Sin
Inhibition of CDC27 O-GlcNAcylation coordinates the antitumor efficacy in multiple myeloma through the autophagy-lysosome pathway. [Abstract]2025 Jul;46(7):2041-2055. PMID: 39984622 -
-
Clin Sci
Glutamine alleviates immunosuppression in polymicrobial sepsis by augmenting bacterial phagocytosis through sustaining the GFAT-DRP1 dependent mitochondrial calcium dynamics. [Abstract]2025 Oct 22;139(20):1163-1185. PMID: 41082631 -
Cell Death Discov
2023 May 15;9(1):163. PMID: 37188682 -
Clin Transl Med
Androgen-repressed lncRNA LINC01126 drives castration-resistant prostate cancer by regulating the switch between O-GlcNAcylation and phosphorylation of androgen receptor. [Abstract]2024 Jan;14(1):e1531. PMID: 38214432 -
J Anim Sci Biotechnol
HIF1A regulates follicular atresia through O-GlcNAcylation-mediated VEZF1/ET-1/FOXO1/BAX signaling in porcine granulosa cells. [Abstract]2025 Sep 20;16(1):127. PMID: 40973947 -
Mol Med
New perspectives on YTHDF2 O-GlcNAc modification in the pathogenesis of intervertebral disc degeneration. [Abstract]2024 Oct 18;30(1):180. PMID: 39425013 -
Ecotoxicol Environ Saf
SMAD4 promotes EMT in COPD airway remodeling induced by cigarette smoke through interaction with O-GlcNAc transferase. [Abstract]2024 Aug 23:284:116931. PMID: 39181074 -
Commun Biol
TRIM21 promotes K63-linked ubiquitination of ALKBH5 and suppresses cuproptosis via down-regulation of LIAS in esophageal squamous cell carcinoma. [Abstract]2025 Dec 18;8(1):1783. PMID: 41413718 -
Commun Biol
Endoplasmic reticulum-mitochondria coupling prompts ZBP1-mediated RPE cell PANoptosis in age-related macular degeneration. [Abstract]2025 Jul 29;8(1):1118. PMID: 40731132 -
J Nutr Biochem
Promoter demethylation and protein O-GlcNAcylation-mediated enhancement of fatty acid synthase contributes to hepatic steatosis and inflammation in MASLD. [Abstract]2025 Dec 6:150:110227. PMID: 41360204 -
Int J Oncol
O‑GlcNAcylation mediates endometrial cancer progression by regulating the Hippo‑YAP pathway. [Abstract]2023 Aug;63(2):90. PMID: 37350405 -
Int Immunopharmacol
Fluzoparib disrupts Golgi apparatus to inhibit O-GlcNAcylation and nuclear translocation of β-catenin to attenuate ovarian cancer invasion and metastasis. [Abstract]2025 Sep 23:162:115158. PMID: 40602265 -
Mol Pharm
Sialic Acid-Modified O-GlcNAc Transferase Inhibitor Liposome Presents Antitumor Effect in Hepatocellular Carcinoma. [Abstract]2024 Jan 1;21(1):102-112. PMID: 37994899 -
J Physiol
Hyperglycaemia-induced reactive oxygen species production in cardiac ventricular myocytes differs among mammals. [Abstract]2025 May 11. PMID: 40349305 -
Biochim Biophys Acta Mol Basis Dis
Targeted inhibition of the H3K27ac/OGT/O-GlcNAcylation axis to overcome gemcitabine-induced chemotherapy resistance in bladder cancer. [Abstract]2026 Aug;1872(6):168281. PMID: 42069092 -
FASEB J
Desaminotyrosine is a redox-active microbial metabolite that bolsters macrophage antimicrobial functions while attenuating IL-6 production. [Abstract]2024 Jul 31;38(14):e23844. PMID: 39046365 -
Cell Signal
O-GlcNAcylation-mediated glycolytic reprogramming of CD4+ T cells contributes to type H vessel impairment in diabetic osteoporosis. [Abstract]2026 Jun 26:146:112694. PMID: 42361945 -
Reproduction
High dietary fructose induces the senescence of granulosa cells by enhancing O-GlcNAcylation. [Abstract]2026 Feb 5;171(2):xaag005. PMID: 41575286 -
Int Dent J
High-Glucose Microenvironment Accelerates Malignant Progression Via O-GlcNAcylation in Oral Squamous Cell Carcinoma. [Abstract]2025 Oct 8;75(6):103897. PMID: 41067097 -
Cytokine
Downregulation of GFPT2 enhances cisplatin chemotherapy sensitivity in STK11/KRAS mutant non-small cell lung cancer by regulating the hexosamine biosynthesis pathway, resisting tumor growth. [Abstract]2025 Apr 19:191:156943. PMID: 40253947 -
Mol Hum Reprod
O-GlcNAcylation orchestrates porcine oocyte maturation through maintaining mitochondrial dynamics and function. [Abstract]2024 Feb 1;30(2):gaae003. PMID: 38265252 -
Toxicol Appl Pharmacol
Resveratrol alleviates inflammatory bowel disease by inhibiting JAK2/STAT3 pathway activity via the reduction of O-GlcNAcylation of STAT3 in intestinal epithelial cells. [Abstract]2024 Mar:484:116882. PMID: 38437956 -
Am J Physiol Gastrointest Liver Physiol
Low-dose galactose rebalances HBP-mTORC1-SREBP-1c signaling to suppress hepatic lipogenesis and protect against early-stage alcohol-related liver disease. [Abstract]2026 Feb 1;330(2):G170-G188. PMID: 41528029 -
Am J Physiol Gastrointest Liver Physiol
Glucose metabolism through the hexosamine biosynthetic pathway drives hepatic de novo lipogenesis via promoting N-linked protein glycosylation. [Abstract]2025 Jun 1;328(6):G746-G759. PMID: 40331866 -
Funct Integr Genomics
2026 May 25;26(1):109. PMID: 42183899 -
Autoimmunity
High glucose promotes O-GlcNAcylation of ACSL4 to induce ferroptosis of renal tubular epithelial cell. [Abstract]2025 Dec;58(1):2576881. PMID: 41133730 -
Microvasc Res
Hypoglycaemia aggravates impaired endothelial-dependent vasodilation in diabetes by suppressing endothelial nitric oxide synthase activity and stimulating inducible nitric oxide synthase expression. [Abstract]2023 Mar:146:104468. PMID: 36513147 -
PLoS One
Reducing OGT and O-GlcNAcylation enhance the anticancer effects of oxaliplatin in SW620 metastatic colorectal cancer cells. [Abstract]2026 Feb 10;21(2):e0341971. PMID: 41666153 -
Immunol Invest
Astragalus Polysaccharide Promotes NLRP3+ Macrophages Polarization via Suppression of OGT in Hepatocellular Carcinoma. [Abstract]2026 May;55(4):750-773. PMID: 41877503 -
Toxicon
Toosendanin sensitizes hepatocyte ferroptosis via dual inhibition of Nrf2 O-GlcNAcylation and USP7-driven deubiquitination. [Abstract]2026 Apr 1:273:109018. PMID: 41628670 -
Biochem Biophys Res Commun
O-GlcNAcylation of NSD2 promotes lung metastasis of triple-negative breast cancer through extracellular matrix remodeling. [Abstract]2026 Aug 20:827:154043. PMID: 42217410 -
-
-
-
-
-
Solvant et solubilité
DMSO : 100 mg/mL (177.42 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 2.08 mg/mL (3.69 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.08 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (281 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Ortiz-Meoz RF, et al. A small molecule that inhibits OGT activity in cells. ACS Chem Biol. 2015 Jun 19;10(6):1392-7. [Content Brief]
[2]. Liu Y, et al. Discovery of a Low Toxicity O-GlcNAc Transferase (OGT) Inhibitor by Structure-based Virtual Screening of Natural Products. Sci Rep. 2017 Sep 26;7(1):12334. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.7742 mL | 8.8709 mL | 17.7418 mL | 44.3546 mL |
| 5 mM | 0.3548 mL | 1.7742 mL | 3.5484 mL | 8.8709 mL | |
| 10 mM | 0.1774 mL | 0.8871 mL | 1.7742 mL | 4.4355 mL | |
| 15 mM | 0.1183 mL | 0.5914 mL | 1.1828 mL | 2.9570 mL | |
| 20 mM | 0.0887 mL | 0.4435 mL | 0.8871 mL | 2.2177 mL | |
| 25 mM | 0.0710 mL | 0.3548 mL | 0.7097 mL | 1.7742 mL | |
| 30 mM | 0.0591 mL | 0.2957 mL | 0.5914 mL | 1.4785 mL | |
| 40 mM | 0.0444 mL | 0.2218 mL | 0.4435 mL | 1.1089 mL | |
| 50 mM | 0.0355 mL | 0.1774 mL | 0.3548 mL | 0.8871 mL | |
| 60 mM | 0.0296 mL | 0.1478 mL | 0.2957 mL | 0.7392 mL | |
| 80 mM | 0.0222 mL | 0.1109 mL | 0.2218 mL | 0.5544 mL | |
| 100 mM | 0.0177 mL | 0.0887 mL | 0.1774 mL | 0.4435 mL |
OSMI-1 Related Classifications
HY-119738 Related Classifications
Powered by Bioz